Antibiotic Resistance and Antibiotic Technologies: Global Markets

According to a new technical market research report, Antibiotic Resistance and Antibiotic Technologies: Global Markets (PHM025B) from BCC Research (www.bccresearch.com), the value of current antibiotics and new products in the global market is an estimated $41.5 billion in 2009, but is expected to increase to $65.5 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 9.6%.

The largest segment of the market, antibiotic drugs, is projected to grow at a CAGR of 5.9% to reach $50 billion in 2014. Its value is estimated at $37.6 billion in 2009.

Bacterial vaccines, the other segment of the market, is estimated at $3.9 billion in 2009, and is expected to increase at a 5-year CAGR of 31.6% to reach $15.5 billion in 2014.

Antibiotic resistance is a major health crisis throughout the world that requires an intensely focused action plan. Although resistance cannot be prevented, the problem is exacerbated by the fact that the pipeline targeting it is very lean, as the field was neglected by the industry for a long time.

The antibiotics sector is witnessing a new wave of interest in terms of investment, which is leading to innovation that was absent for more than two decades. The bacterial vaccines sector is expected to show particularly commendable growth trends during the 2009-2014 forecast period.

Regulatory trends emerging in various markets are expected to play key roles in the market growth. Because the best way to contain the resistance problem is to restrict the use of these products, it is expected to have a negative effect on the sector’s market growth. This is especially true for the established antibiotic classes that are facing serious resistance issues. Thus, the use of new classes of antibiotics will be encouraged, which will drive market growth.

This report is valuable reading for investors, policy makers, and industry participants.

Analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs.

Generic Drugs: The Global Market

According to a technical market research report, Generic Drugs: The Global Market from BCC Research (PHM009E) (www.bccresearch.com), the global market for generic drugs was worth $84 billion in 2009, a figure that is expected to reach $129.3 billion in 2014, for a compound annual growth rate (CAGR) of 9% over the 5-year forecast period.


The generic market came of age during the 1990s and the generic industry consolidated its position during the first years of the new millennium. Starting as a patchwork of national marketplaces, the generic world now rivals the traditional pharmaceutical universe.

However, this is a volatile time for the generic pharmaceutical sector. The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time, fierce price competition is resulting in slashed profit margins for participating companies. A major growth driver for the generics sector is that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition. And the international landscape is changing for generics as for all pharmaceuticals. China, India, Eastern European countries and Brazil are among rising centers of generic activity.

This report, Generic Drugs: The Global Market, values the current global generics market in developed countries at an estimated $59 billion. Of the latter figure, the five major European national markets account for 23%, the U.S. for 42%, and Japan for 6%.

Generic penetration varies widely from country to country; in Europe, for example, generics account for almost 18% of the German pharmaceutical market but only 11% of the pharma market in France. The European average share is 15%; this compares with 10% of the U.S. pharmaceutical market, but only 6% of the market in Japan.

In terms of growth, generics have outstripped “regular” pharmaceuticals and seem certain to grow more quickly during the next decade, driven by:

• Aging populations, especially in developed countries, driving up the costs of healthcare including drugs

• Problems faced by payers (governments, HMOs, individuals) in attempting to pay for expensive branded pharmaceuticals

• General economic downturn exacerbating the above problems

• Emergence of new national markets for pharmaceuticals among developing economies, needing to install affordable healthcare systems

• Wider access to information about pharmaceuticals via the internet, leading to fuller appreciation of the value of generics in the public domain

• Increasing involvement of “big pharma” in the generics arena, improving the public perception and acceptance of generics

• Loss of patent protection by a succession of blockbuster products, creating new opportunities for generics.

Although the worldwide economic downturn which began to take hold in 2008 led to slower growth for pharmaceuticals overall, the negative effect was less marked in the generic sector, and in the medium to long term it is expected that generic markets will continue to show positive growth, and at a faster rate than mainstream pharma.

Global Anti-aging Market for the Boomer Generation Worth $274.5 Billion In 2013

The global anti-aging market for the boomer generation (born between 1946-65) was worth $162.2 billion in 2008. This will increase to $274.5 billion in 2013, for a compound annual growth rate (CAGR) of 11.1%.

The market is broken down into segments for appearance, disease and fitness. The disease treatment segment currently has the largest share of the market, worth $66.0 billion in 2008. This should increase at a CAGR of 12.5% to reach $119.2 billion in 2013.

The appearance segment has the second largest share of the market, worth $64.4 billion in 2008. This segment is expected to generate $105.4 billion in 2013, for a CAGR of 10.4%.

The fitness segment has the third largest market share and was worth $31.8 billion in 2008. This is expected to reach $49.8 billion in 2013, for a CAGR of 9.4%.

The appearance market consists of the facial rejuvenation, skin rejuvenation, hair care and body shaping markets. The disease management market consists of preventive and reactive health care for all the diseases of aging such as joint and bone health, Alzheimer’s, sexual dysfunction, metabolic disorders, eye and cardiovascular diseases. The fitness market consists of gym, spa and massage services.

The global anti-aging market is further categorized by the products market and services market. The majority of the products include facial care, skin care, hair care, drugs and supplements, nutraceuticals, cosmetic equipment and fitness equipment. The majority of the services market includes cosmetic invasive and noninvasive services, complementary and alternative medicine therapies, bioregenerative services, spa treatments and massages, and gym services.

The services market accounts for a major portion of the global anti-aging market, or around 54.2% in 2008, and will increase to 55.6% in 2013, for a CAGR 11.7%. The products market will increase from $73.3 billion in 2008 to $199.9 billion in 2013, for a CAGR 10.4%

Preventive Healthcare Technologies, Products and Markets

According to a new technical market research report, PREVENTIVE HEALTHCARE TECHNOLOGIES, PRODUCTS, AND MARKETS (HLC070A) from BCC Research, the global market for new preventive healthcare technologies is valued at an estimated $11 billion in 2009, but is expected to increase to nearly $16.2 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 8.2%.

The largest segment of the market, products, is projected to reach $12.2 billion in 2014, after increasing at a CAGR of 7.4% from the 2009 value of $8.5 billion.

The services segment is estimated at $2.4 billion in 2009, and is expected to reach $4 billion in 2014, for a 5-year CAGR of 10.8%.

Preventive healthcare is likely to be an important component of any plan to restructure the U.S. healthcare system. At present, between 4% and 8% of the $2.4 trillion the U.S. spends annually on healthcare (i.e., $96 billion to $192 billion) goes for preventive care.

Broadly defined, preventive healthcare includes everything from over-the-counter (OTC) products designed to help users curb smoking or overeating to advanced genetic testing to identify a predisposition to certain cancers or other health problems. This report, however, focuses on a group of advanced preventive healthcare technologies and services.

Some of these technologies, such as certain vaccines, are decades old, while others (e.g., cytomics) are still largely at the experimental stage for clinical applications. This report generally focuses on new or emerging technologies, without being too rigid about what constitutes a “new” technology. Areas of particular interest include genomics, proteomics, cytomics, radiology, nanotechnology, informatics, and automation.

The report is intended especially for vendors of preventive healthcare-related products and services, as well as government agencies, healthcare policy analysts, and others seeking to understand the cost and preconditions for success of preventive healthcare initiatives.

Regenerative Medicines: Bone and Joint Applications

According to a new technical market research report, REGENERATIVE MEDICINES: BONE AND JOINT APPLICATIONS (PHM032B) from BCC Research (www.bccresearch.com), the value of the global market for regenerative medicines is an estimated $1.2 billion in 2009, but is expected to increase to $1.8 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 8.6%.



The largest segment of the market, bone replacement/grafting, is projected to grow at a CAGR of 6.3% to reach $979 million in 2014. Its value is estimated at $721 million in 2009.


Bone growth stimulators, the second-largest segment, is estimated at $330 million in 2009, and is expected to increase at a 5-year CAGR of 11.9% to reach $578 million in 2014.


The smallest segment, tissue engineering/cartilage, is projected to reach $207 million in 2014, after rising at a CAGR of 12.5% from the 2009 estimate of $115 million.


Regenerative medicine is an area of research and product development that shows great promise in treating or curing diseases and conditions that currently have limited or no treatment options, such as blindness, deafness, bone and cartilage damage, neurodegeneration, diabetes, and heart disease. Although science is still a long way from regrowing new limbs or organs, stem cell research and its applications in regenerative medicine currently offer an opportunity to develop the first generation of therapeutics to do what has never before seemed possible.


The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important. The study provides a comprehensive analysis of the current markets for regenerative medicine products, relevant applications, and the potential of products in development.


The information and analysis presented are important assets in decision making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking, and deal creation, as well as to consultants to the pharmaceutical and biotechnology industries.

Contract Pharmaceuticals Manufacturing, Research, and Packaging

The global market for contract pharmaceuticals is worth an estimated $177 billion in 2009, and is expected to increase to $299 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 11.1%.



The largest segment of the market, contract manufacture of over-the-counter (OTC) and nutraceuticals, is projected to increase at a CAGR of 11.4% to reach $177 billion by 2014, rising from an estimated $103.1 billion in 2009.


Contract manufacture of bulk- and dosage-form drugs, the second-largest segment, is estimated to be worth nearly $44 billion in 2009, and is projected to increase at a CAGR of 10.8% to reach $73.1 billion in 2014.


The third-largest segment, contract research, is expected to reach $40.6 billion in 2014, for a 5-year CAGR of 10.7%. Its 2009 value is estimated at $24.4 billion.


The smallest segment, contract packaging, is projected to have a CAGR of 8%, increasing from $5.5 billion in 2009 to $8.1 billion in 2014.


Many pharmaceutical companies choose outsourcing as an option, or choice, to better market their products without spending time in drug discovery and the manufacturing process. These pharmaceutical companies rely on contract manufacturers and researchers. This study examines the different types of contracting companies in the pharmaceuticals industry. BCC analyzes each market and its applications by its need for outsourcing, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.


Pharmaceutical and biopharmaceutical companies are dependent on the contracting companies due to increased generic competition, declining R&D productivity, rising drug development costs, constricting patent life, and fewer drug discoveries. With the increasing demand to reduce capital expenditures and protect their margins, pharmaceutical companies are outsourcing their non-core activities, such as active pharmaceutical ingredients (API) and intermediates manufacturing, to low-cost destinations like India and China. This study contributes to the areas of growth in this market sector from the point of view of manufacturers and users. Biochemical companies, physicians, the pharmaceuticals and biopharmaceuticals industries, and research companies will find value in this study.

Renal Disease Treatments: Products and Therapies

The global market for renal disease treatments is an estimated $28 billion in 2009, but is expected to increase to $33.5 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 3.7%.

The largest segment of the market, chronic kidney disease (CKD) treatment products and therapies, is estimated to be nearly $27 billion in 2009, and is expected to increase at a CAGR of 3.6% through 2014 to reach nearly $32 billion.

The second-largest segment, acute renal failure (ARF) treatment products and therapies, is projected to grow at an 8.7% CAGR, from an estimated $955 million in 2009 to nearly $1.5 billion in 2014.

The smallest segment of the market, equipment, is projected to increase at a CAGR of 3.4%, from revenues of $276 million in 2009 to $326 million in 2014.

Renal failure can be either acute and temporary, or chronic and mostly irreversible. Either form may be due to a large number of other medical problems; long-term kidney problems have significant repercussions on other diseases. Once kidney failure is detected, the goal is preventing further deterioration of renal function.

The renal disease treatment market includes pharmaceutical products, renal replacement therapies, and surgical procedures. The choice of intervention largely depends on how far kidney failure has advanced and whether the condition is short term or permanent. Driving forces include an aging population, poor management of disease states, underlying kidney disease, and the increasing severity of illness of hospitalized patients.

This study aims to provide those interested in investment, acquisition, or expansion into the renal failure treatment market with specific, detailed information crucial to making informed decisions. Senior marketing personnel, venture capitalists, executive planners, and research directors should find the report of value.

Advanced Materials and Devices for Renewable Energy

The global market for advanced materials and devices for renewable energy is estimated to be worth $11.6 billion in 2009, but is expected to increase to $16.9 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 7.8%.

The largest segment of the market, solar energy (photovoltaics and thermal), is expected to increase to $13.1 billion in 2014, after rising at a CAGR of 9.5% from the 2009 value of $8.3 billion.

The second-largest segment, wind energy, is estimated to be worth $3.3 billion in 2009, and is projected to increase at a CAGR of 1.7% to reach $3.6 billion in 2014.

The geothermal energy segment is expected to reach $14 million in 2014, after rising at a CAGR of 19.3% from the 2009 value of $5.8 million.

The greatest amount of growth – at a CAGR of 193.6% – in the next five years is expected to occur in the small hydro and ocean energy sector. A value of $1.1 million in 2009 is projected to grow to $240.1 million in 2014.

This report focuses on the global market for advanced materials (e.g., polymers, elastomers, composites, high-temperature alloys, powder metals, thin films, and others) and devices (sensors and controllers, optics, etc.) used in the fabrication of solar-photovoltaic, solar-thermal, mini- and micro-hydro, wind, geothermal, and ocean renewable-energy devices and systems.

It is intended especially for developers and vendors of advanced materials and devices that target the renewable-energy systems market. It should also be useful to vendors of renewable-energy systems interested in understanding where the market is headed with respect to advanced enabling technologies. While the report is oriented to the interests and concerns of a nontechnical audience, it contains a great deal of technical information that should be of interest to scientists and engineers working in the renewable-energy field.

Energy and environment related business intelligence opportunities

There are huge expectations out of the United Nations Climate Change Conference 2009 at Copenhagen, Denmark from December 7-18 2009 and businesses will greatly be affected in the coming years due to policy/regulatory decisions. What will ultimately matter more though are consumer attitudes towards environment related issues and the potential of new business opportunities that are being created in this context.

With BCC Research market research reports you get an expert in-depth analysis of the various opportunities that environment and energy related issues offer, backed by over 35 years of experience in catering to the research needs of small and large businesses, government and academia.

Our featured reports (with free introductory chapters) include:

The U.S. Market for Green Building Materials

Global Markets for Industrial and Utility Solar Thermal Technologies

Energy Efficient Technologies: The Global Market

Air Pollution Control for Coal Fired Power Plants

Energy from Wind and Waves: The Global Market

Advanced Materials and Devices for Renewable Energy

Global Markets for Residential and Commercial Solar Thermal Technologies

Thermal and Biological Waste-to-Energy Markets

Enabling Technologies for the Smart Grid

The Market for Liquid Biofuels Outside North America

Nanotechnology in Environmental Applications: The Global Market

Lithium Batteries: Markets and Materials
 
Hybrid & Electric Vehicle Progress Review

Environmental Sensing and Monitoring Technologies: Global Markets

Organic Light Emitting Diodes (OLEDs): Technologies and Global Markets

The US Market for Clean Technologies

Membrane Bioreactors: Global Markets

Sludge Treatment: The Global Market

Seawater and Brackish Water Desalination

Environment Protection Market in China

Global Markets for Residential and Commercial Solar Thermal Technologies

The global market for residential and commercial solar-thermal technologies is worth an estimated $8 billion in 2009, but is expected to increase to nearly $20 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 19,8%.

The largest segment of the market, water heating, is estimated to be worth $7.9 billion in 2009, and is projected to grow at a CAGR of 19.9% to reach $19.6 billion in 2014.

The smaller segment, air heating, is expected to reach nearly $92 million in 2014, after increasing at a 5-year CAGR of 7.9% from $62.5 million in 2009.

Residential and commercial solar-thermal technologies include products that capture, concentrate, and/or absorb sunlight to provide thermal energy to a particular process or system. Because all residential and commercial solar-thermal installations must include a component that collects solar radiation, solar-thermal collectors and absorbers provide excellent indicators regarding the market performance and penetration of residential and commercial solar-thermal systems.

The following residential and commercial solar-thermal technologies are included in the scope of this report: unglazed solar collectors, flat-plate solar collectors, evacuated-tube solar collectors, integral collector storage, concentrating solar collectors, glazed solar air collectors, and transpired solar air collectors.

This study will be of interest to manufacturers of solar-thermal technologies, distributors, suppliers, and entrepreneurs and entrepreneurial companies interested in entering or expanding into the solar-thermal technology sector. It will also be of interest to corporate planners and strategists, large commercial and industrial energy consumers, energy market researchers, solar energy advocacy groups, and other public- and private-sector interest groups and market analysts.